A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors
Status:
Recruiting
Trial end date:
2026-07-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of BMS-986406 administered
alone, in combination with nivolumab, or in combination with nivolumab and platinum-doublet
chemotherapy (PDCT) in participants with advanced tumors.